权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functionalized Lipid Carriers for Nucleic-Acid and Drug Therapeutics

用于核酸和药物治疗的功能化脂质载体

基本信息

批准号：
10020420
负责人：
CYRUS R SAFINYA
金额：
$ 29.56万
依托单位：
UNIVERSITY OF CALIFORNIA SANTA BARBARA
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-20 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10020420
关键词：
Achievement Acids Adhesions Albumin-Stabilized Nanoparticle Paclitaxel Biological Biological Assay Biophysics Cancer cell line Capsid Cations Cell Survival Cells Charge Chemicals Chemistry Chemotherapy-Oncologic Procedure Clinical Trials Code Communities Complex Cone Custom Cyclic Peptides Cytosol DNA Data Dependence Development Distal Drug Delivery Systems Electron Microscopy Electrostatics Encapsulated Endosomes Engineering Excision Exons Fluorescence Microscopy Gene Delivery Gene Silencing Genes Goals Homing Hospitals Human Hydrophobicity Hypersensitivity In Vitro Introns Knowledge Laboratories Ligands Lipid Bilayers Lipids Liposomes Malignant Neoplasms Mediating Membrane Methods Micelles Modernization Non-Viral Vector Nucleic Acids Organelles Organic Chemistry Paclitaxel Penetration Peptides Pharmaceutical Preparations Phase Probability Property Proteins RNA Reaction Research Research Activity Roentgen Rays Safety Science Shapes Small Interfering RNA Solid Solubility Structure Synchrotrons Tail Techniques Testing Therapeutic Transfection Tumor Tissue Untranslated RNA Vesicle Viral Vector Virus X ray diffraction analysis base biophysical analysis biophysical properties biophysical techniques cancer cell chemical property cryogenics cytotoxic cytotoxicity design disorder control efficacy testing ethylene glycol gene therapy human model immunogenic immunogenicity in vivo liposome vector malignant stomach neoplasm mouse model nanoparticle nanoscale novel nucleic acid delivery nucleic acid-based therapeutics physical property tool tumor uptake vector

项目摘要

Project Summary/Abstract The current level of research activity involving gene therapy with either synthetic vectors (carriers) or engineered viruses is unprecedented. Liposomes are the most widely studied nonviral carriers worldwide for nucleic acid (NA) and drug delivery applications. Cationic liposomes (CLs) are relatively safe nonviral vectors used in ongoing clinical trials. CLs may either be complexed via electrostatic interactions with therapeutic NAs (anionic DNA or short interfering RNA) for gene delivery and silencing, or used as vectors of potent cytotoxic hydrophobic drugs, encapsulated within their lipid bilayer, in cancer therapeutics. Among the biggest advantages of nonviral vectors (over viral vectors which are currently more efficient in in vivo settings) are their safety, their low immunogenicity and their ability to transfer entire genes (containing coding and noncoding sequences) and regulatory sequences into cells (currently not feasible with engineered viruses because of capsid size limitations). The development of nonviral lipid-based vectors with efficacy competitive with viral vectors in vivo will require a mechanistic understanding of how synthetic vectors may be functionalized to overcome the major intracellular hurdle of endosomal escape. Successful endosomal escape is required for release of therapeutic nucleic acid within the cell cytosol and therefore maximum efficacy. The first aim of this research application is to employ modern biophysical and synthetic approaches to the rational design of functionalized CL–NA nanoparticles (NPs) with synergistic, complementary dual-function PEG-lipid and fusogenic components for optimized endosomal escape. Modern methods of organic and solid phase chemistry will be employed to synthesize dual-function PEG-lipids with cell targeting and endosome escaping properties. The second aim of this research application is to optimize efficacy of a new class of CL-based carriers of the hydrophobic drug paclitaxel (PTXL) for cancer therapeutics. This will be achieved by developing a mechanistic understanding of the relation between physical and chemical properties of the carrier (i.e. size of the functionalized CL carrier, membrane spontaneous curvature, and lipid tail structure) and functional efficacy (i.e. PTXL membrane solubility, cell uptake of vector and PTXL delivery leading to cytotoxicity against human cancer cells). The structures of CL-based vectors of NAs and hydrophobic drugs will be characterized using cryogenic electron microscopy and synchrotron x-ray diffraction techniques. The interactions between CL vectors and cell organelles will be directly visualized with spinning disk confocal fluorescence microscopy. Their structures will be correlated to their biological activity in human cancer cells. The broad, long-term objective of our research is to develop a fundamental science base through mechanistic studies that will lead to the design and synthesis of nonviral vectors of nucleic acids and hydrophobic drugs for gene and cancer therapeutics.

项目总结/文摘